NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...
VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL, March 9...
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...
MONTREAL, March 06, 2023 (GLOBE NEWSWIRE) -- Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC Canada NewsWire MONTREAL, Feb. 7, 2023...
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE...
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST Canada...
VALEO PHARMA ANNOUNCES SENIOR MANAGEMENT CHANGE Canada NewsWire MONTREAL, Nov. 21, 2022 Valeo's President...
VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE Canada NewsWire MONTREAL, Nov. 15, 2022 Q4-2022...
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH...
VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL, Sept. 9...
VALEO PHARMA ADDS PHARMACEUTICAL INDUSTRY VETERAN KYLE STEIGER TO LEADERSHIP TEAM Canada NewsWire MONTREAL...
VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS Canada...
VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT® Canada...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.